Late Breaking Abstract - Anti-IL-4 and anti-IL-13 dual vaccination using Kinoid technology prevents development of allergic asthma in mice Source: International Congress 2019 – New towards old therapies in airway diseases Year: 2019
Late Breaking Abstract - Durable clinical benefit of benralizumab following oral corticosteroid reduction: The PONENTE study Source: Virtual Congress 2021 – Severe asthma: evaluation using patient-reported outcome measures (PROMs) and biomarkers, comorbidities and treatments Year: 2021
Novel inhaled delivery of anti-IL-13 mAb (Fab fragment): preclinical efficacy in allergic asthma Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies Year: 2017
Phase 1 study of a novel, prolonged-action anti-IL-5 monoclonal antibody in asthma Source: Virtual Congress 2021 – Clinical trials in airway diseases: novel treatments and new evidence Year: 2021
Late Breaking Abstract - Multiple ascending dose study of the inhaled IL-4Ra antagonist, AZD1402/PRS-060, in mild asthmatics demonstrates robust FeNO reduction and a promising clinical profile for the treatment of asthma Source: International Congress 2019 – Asthma treatment: novel insights from clinical studies Year: 2019
Preclinical development of an IL-13 neutralising antibody, CAT-354, for the treatment of human asthma Source: Eur Respir J 2005; 26: Suppl. 49, 367s Year: 2005
Late Breaking Abstract - A PET imaging study to confirm target engagement in the lungs of patients with IPF following a single dose of a novel inhaled avß6 integrin inhibitor Source: International Congress 2019 – Idiopathic pulmonary fibrosis and surroundings Year: 2019
Safety profile and clinical activity of multiple subcutaneous (SC) doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in subjects with asthma Source: Annual Congress 2010 - Novel anti-inflammatory agents for airway disease Year: 2010
Late Breaking Abstract - Two-year cumulative oral corticosteroid exposure in severe eosinophilic asthma before and after anti-IL-5 therapy Source: Virtual Congress 2021 – Advances in asthma treatment Year: 2021
Efficacy of inhaled anti-IL-13 mAb in a mouse model of asthma Source: Annual Congress 2011 - Experimental modulation of airway inflammation Year: 2011
The real world effectiveness and effect on adherence with inhaled asthma therapy of 1 year of Severe Asthma Monoclonal Antibody Treatment Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020
Late Breaking Abstract - ND-L02-s0201 treatment leads to efficacy in preclinical IPF models Source: International Congress 2017 – The spectrum of CTDs: from pathogenesis to treatment Year: 2017
Late Breaking Abstract - The burden of intermittent oral corticosteroid use in asthma Source: Virtual Congress 2021 – Asthma treatment: clinical and translational science Year: 2021
The effect of anti-IL-33 antibody and soluble ST2 in a murine model of allergic asthma Source: Annual Congress 2013 –Murine models of lung immunology Year: 2013
Treatment with omalizumab (rhuMAb-E25), a monoclonal anti-IgE antibody induces effective changes in subjects with allergic asthma Source: Eur Respir J 2001; 18: Suppl. 33, 37s Year: 2001
Treatment of asthma above and beyond anti IgE: an update for the clinician The use of biologicals in asthma treatment Source: International Congress 2018 – Difficult paediatric lung disease Year: 2018
Late Breaking Abstract - The biological pathways underlying response to anti-IL-17A (AIN457; secukinumab) therapy differ across severe asthmatic patients. Source: International Congress 2017 – Update and new perspectives in Airway Diseases Year: 2017
Late Breaking Abstract - PK/PD assessment of an oral, selective aVß6/aVß1 integrin dual antagonist, PLN-74809, for the treatment of idiopathic pulmonary fibrosis Source: International Congress 2019 – Translational aspects of idiopathic interstitial pneumonia Year: 2019
Late Breaking Abstract - Short-term and maintenance oral corticosteroid use for German patients with asthma Source: International Congress 2019 – Powerful cohort studies with/without lung function Year: 2019
Effects of anti-M1 prime monoclonal antibody, MEMP1972A following allergen challenge in patients with mild asthma Source: Annual Congress 2012 - New bronchodilators and other novel drugs for asthma and COPD Year: 2012